Dr. Trefa Yousif , Dr. Sawen Khasrow Dizay
International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-5,Issue-4, July - August 2021, Pages 1-8 , 10.22161/ijmpd.5.4.1
Download | Downloads : 4 | Total View : 298
Article Info: Received: 25 May 2021; Received in revised form: 19 Jun 2021; Accepted: 30 Jun 2021; Available online: 07 Jul 2021
The purpose of this study was to determine the accuracy of screening for pregnancy hypertension disorders using maternal serum biomarkers and uterine artery Doppler during the first trimester. At 11-13 weeks, uterine artery Doppler and serum measurements were taken from prospectively enrolled nulliparous women. In this study, maternal features, uterine artery Doppler imaging, and serum placental biomarkers (pregnancy-associated plasma protein-A, Inhibin-A, placental protein, A disintegrin and metalloprotease, free B-hCG, placental growth factor) were all collected and evaluated. Twenty women (2.2 percent) experienced prenatal hypertension, and forty women (4.5 percent) developed preeclampsia, with nine (1.0 percent) developing early-onset preeclampsia and sixteen (1.8 percent) developing severe preeclampsia, according to the findings. A combination screening model that included clinical features, pregnancy-associated plasma protein-A, Inhibin-A, and placental growth factor was found to be effective in detecting 75 percent of early-onset preeclampsia with a false-positive rate of 10 percent. Uterine artery Doppler, placental protein, A disintegrin and metalloprotease were all found to have no effect on diagnosis accuracy after adjusting for clinical factors. When combined with first-trimester maternal serum biomarkers (pregnancy-associated plasma protein-A, Inhibin-A, and placental growth factor), a combination of clinical features and placental growth factor can give an accurate screening for early-onset preeclampsia in nulliparous women.